[Experimental study of sensitivity to chemotherapeutic agents for human endometrial carcinoma cell line]

Zhonghua Zhong Liu Za Zhi. 2004 Jul;26(7):409-12.
[Article in Chinese]

Abstract

Objective: To screen the sensitive chemotherapeutic agents to human endometrial carcinoma cell line-1 (HECCL-1) and study its mechanism.

Methods: MTT method was used to examine the relative inhibition ratios (RIRs) of various concentrations of 18 chemotherapeutic agents to HECCL-1. Cell cycle, apoptosis and expression of MDR1 protein were detected by FCM.

Results: Nine of the chemotherapeutic agents studied obviously inhibited the proliferative activity of HECCL-1 in a dose-dependent manner. The order of sensitivity was as follows: adriamycin (ADM), oxaliplatin (L-OHP), carboplatin (CBP), cisplatin (DDP), taxol (TAL), epirubicin (EPI), mitoxantrone (MIT), dactomycin (ACTD) and 5-fluorouracil (5-Fu). FCM showed these agents could significantly reduce the proportion of cells in G0-G1 phase, and increase the proportion of cells in S and G2-M phase (P < 0.05). Cell apoptosis was observed in 11 chemotherapeutic agents at their peak concentration. MDR expression was induced after using EPI, 5-Fu, hydroxycamptothecin (HCPT) and MIT.

Conclusion: HECCL-1 is sensitive to a number of the chemotherapeutic agents studied. Induced apoptosis may be the major mechanism of drug sensitivity, and acquired drug-resistance may be the critical reason against continued administration.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Carboplatin / administration & dosage
  • Carboplatin / pharmacology
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage
  • Doxorubicin / pharmacology
  • Drug Resistance, Multiple*
  • Drug Resistance, Neoplasm*
  • Endometrial Neoplasms / metabolism
  • Endometrial Neoplasms / pathology*
  • Epirubicin / administration & dosage
  • Epirubicin / pharmacology
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / pharmacology
  • Humans
  • Organoplatinum Compounds / administration & dosage
  • Organoplatinum Compounds / pharmacology
  • Oxaliplatin

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antineoplastic Agents
  • Organoplatinum Compounds
  • Oxaliplatin
  • Epirubicin
  • Doxorubicin
  • Carboplatin
  • Fluorouracil